Filing Details

Accession Number:
0001140361-17-045127
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-05 21:04:41
Reporting Period:
2017-12-01
Accepted Time:
2017-12-05 21:04:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1636282 Aeglea Biotherapeutics Inc. AGLE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532219 G. Anthony Quinn C/O Aeglea Biotherapeutics, Inc.
901 S. Mopac Expressway, Suite 250
Austin TX 78746
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-12-01 4,100 $4.53 14,100 No 4 P Direct
Common Stock Acquisiton 2017-12-04 7,956 $4.98 22,056 No 4 P Direct
Common Stock Acquisiton 2017-12-05 5,065 $4.93 27,121 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.60 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
  3. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.70 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.